Meet in the middle: Could cell mediated‐immunity assays be the answer for ideal Cytomegalovirus prophylaxis after lung transplantation? Observational study from a single center with intermittent antiviral prophylaxis

Author:

Campos Sílvia Vidal1ORCID,Teixeira Lisete Ribeiro1ORCID,Freire Maristela Pinheiro2ORCID,Mamana Ana Carolina3ORCID,Machado Clarisse Martins3ORCID

Affiliation:

1. Pulmonary Division Heart Institute (InCor) University of Sao Paulo Sao Paulo Brazil

2. Infection Control Team Clinical Hospital University of Sao Paulo Sao Paulo Brazil

3. Virology Laboratory (LIM 52 HCFMUSP) Institute of Tropical Medicine University of Sao Paulo Medical School Sao Paulo Brazil

Abstract

AbstractBackgroundCytomegalovirus (CMV) can cause tissue‐invasive disease and indirect effects after lung transplantation (LTx) such as acute rejection episodes and chronic lung allograft dysfunction. Monitoring CMV‐specific cell immune recovery (CMV‐CIR) after LTx can individualize CMV risks and establish better antiviral approach. This study evaluated the dynamics of CMV‐CIR, using QuantiFERON‐CMV assay (Qiagen Group), in the first year after LTx.MethodsProspective observational cohort study included lung transplant recipients from December/2015 to December/2016. Universal antiviral prophylaxis with intravenous ganciclovir 5 mg/kg/day 3 days/week for 3 months was given for CMV‐seropositive recipients (R+) and only CMV‐seropositive donor and negative recipient (D+/R−) received a 6‐month‐prophylaxis with ganciclovir and valganciclovir, on alternate days, in the first 3 months and then, 3 more months of valganciclovir. QuantiFERON‐CMV was measured at the same time points of surveillance bronchoscopies. CMV infection was defined as any DNAemia detected and CMV disease with proven biopsy or antigenemia pp65 above 10 cells/300.000 neutrophils.ResultsThirty‐eight patients were included. On days 45, 90, and 365 days post‐LTx, 60%, 72%, and 81% QuantiFERON‐CMV were reactive, respectively. Eleven patients (28.9%) presented CMV‐disease and 27 DNAemia/CMV infections. Reactive tests were able to predict CMV disease only at 90 days after LTx (p = .027) but failed on DNAemia/CMV infection (p = .148). Daily prophylaxis, for D+/R− patients (13.2%), remained as an independently associated factor for not achieving reactive QuantiFERON‐CMV (adjusted OR .27, 95%CI .12–.60, p = .02).ConclusionQuantiFERON‐CMV may be another diagnostic tool to help stratify CMV‐disease risk and individualized antiviral prophylaxis after LTx. image

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3